IL-24 armored CAR19-T cells show enhanced antitumor activity and persistence
Open Access
- 14 January 2021
- journal article
- letter
- Published by Springer Science and Business Media LLC in Signal Transduction and Targeted Therapy
- Vol. 6 (1), 1-3
- https://doi.org/10.1038/s41392-020-00380-8
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Advances in targeted therapy for malignant lymphomaSignal Transduction and Targeted Therapy, 2020
- Targeted Nanoparticle Drug Delivery System for the Enhancement of Cancer ImmunotherapyJournal of Biomedical Nanotechnology, 2019
- A safe and potent anti-CD19 CAR T cell therapyNature Medicine, 2019
- The application of CAR-T cell therapy in hematological malignancies: advantages and challengesActa Pharmaceutica Sinica. B, 2018
- Low expression of Mda-7/IL-24 and high expression of C-myb in tumour tissues are predictors of poor prognosis for Burkitt lymphoma patientsHematology, 2018